Disorders of gastrointestinal motility: Therapy with motility modifying substances;Störungen der gastrointestinalen motilität: Therapie mit motilitäts-modifizierenden substanzen

Medizinische Monatsschrift fur Pharmazeuten

Volumn 26, Issue 8, 2003, Pages 260-269

  Storr, Martin ^a   Allescher, Hans Dieter ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CHLORO N (8 METHYL 8 AZABICYCLO[3.2.1]OCT 3ALPHA YL) 2 (1 METHYL 2 BUTYNYLOXY)BENZAMIDE; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 8,9 ANHYDRO N ISOPROPYLNORERYTHROMYCIN A 6,9 HEMIACETAL; ALEMCINAL; ALOSETRON; AMITRIPTYLINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTRA MUPS; ATROPINE; BACLOFEN; BOTULINUM TOXIN; BUSPIRONE; CALCIUM ANTAGONIST; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CIMETROPIUM; CISAPRIDE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; FINASTERIDE; GASTROINTESTINAL AGENT; JL 17454; KC 11458; LOPERAMIDE; LOXIGLUMIDE; MEBEVERINE; METOCLOPRAMIDE; MIANSERIN; MORPHINE; MOTILIN[13 LEUCINE]; MUSCLE RELAXANT AGENT; N(G) NITROARGININE; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; OCTREOTIDE; OMEPRAZOLE; ONDANSETRON; PAROMOMYCIN; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; SCOPOLAMINE BUTYL BROMIDE; SIMETHICONE; SUMATRIPTAN SUCCINATE; TEGASEROD; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DYSPHAGIA; ESOPHAGUS SPASM; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HYPERALGESIA; INTESTINE OBSTRUCTION; INTESTINE TRANSIT TIME; MYOTOMY; REVIEW; STOMACH PARESIS;

ESOPHAGEAL MOTILITY DISORDERS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS;

EID: 0042194866     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Albibi R, and McCallum RW. Metoclopramide: Pharmacology and clinical application. Ann Intern Med 1983;98:86-95.
2. Allescher HD, Storr M, Seige M, Gonzales-Donoso R, et al. Treatment of achalasia: Botulinum toxin injection versus pneumatic balloon dilatation - a prospective study with a long-term follow-up. Endoscopy 2001;33:1007-17.
3. Annese V, Basciani M, Perri F, Lombardi G, et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996;111:1418-24.
4. Borovicka J, Kreiss C, Asal K, Remy B, et al. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol 1996;271:G448-53.
5. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-6.
6. Brzana RJ, Koch KL, Bingaman S. Gastric myoelectric activity in patients with gastric outlet obstruction and idiopathic gastroparesis. Am J Gastroenterol 1998;93:1803-9.
7. Camilleri M, Malagelada JR, Abell TL, Brown ML, et al. Effects of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989;96:704-12.
8. Chen JD, Lin ZY, Edmunds MCI, McCallum RW. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig Dis Sci 1998;43:80-9.
9. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987;92:1027-36.
10. Coccia G, Bortolotti M, Michetti P, Dodero M. Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia. Am J Gastroenterol 1992;87:1705-8.
11. De Ponti F, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. Pharmacol Ther 1998;80:49-88.
12. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-37.
13. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996;10:787-93.
14. Farup PG, Hovendak N, Wetterhus S, Lange OJ, et al. The symptomatic effect of cisaprid in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998;33:128-31.
15. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
16. GEMS Study Group. Second report of a multicenter study on electrical stimulation for the treatment of gastroparesis. Gut 1996;39: A103.
17. Gilbert RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, et al. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987;32:1331-6.
18. Hirano I. Pathophysiology of achalasia. Curr Gastroenterol Reports 1999;1:198-202.
19. Hirsch DP, Holloway R, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998;115:1374-80.
20. Holloway RH, Schoeman MN, Dent J. Effect of cisapride on secondary peristalsis in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999;94:799-803.
21. Holtman G, Gschossmann J, Karaus M, Fischer T, et al. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999;13:1459-65.
22. Janisch HD, Huttemann W, Bouzo MH. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology 1988;35:125-7.
23. Janssens J, Peeters TL, Vantrappen G, Tack J, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990;322:1028-31.
24. Jones RH, Holtman G, Rodrigo L, Ehsanullah RSB, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27.
25. Kamiya T, Nagao T, Andou T, Misu N, et al. Effects of trimebutine maleate on gastric motility in patients with gastric ulcer. J Gastroenterol 1998;33:823-7.
26. Lanfranchi GA, Bazzocchi G, Campieri M, Brignola C, et al. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1988;33:571-5.
27. B inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999;117:1147-54.
28. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996;10:595-9.
29. McCallum RW. Gastric emptying in gastroesophageal reflux and the therapeutic role of prokinetic agents. Gastroenterol Clin North Am 1990;19:551-64.
30. McCallum RW. Clinical pharmacology forum: motility agents and the gastrointestinal tract. Am J Med Sci 1996;312:19-26.
31. McHugh S, Lico S, Diamant NE. Cisapride vs metoclopramide. An acute study in diabetic gastroparesis. Dig Dis Sci 1992;37:997-1001.
32. Mertz H, Fulleton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998;42:814-22.
33. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984;86:1592-1610.
34. Mittal R, Holloway R, Penagini R, Blackshaw LA, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-10.
35. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome. Gastroenterology 2000;118:A175.
36. Nomura T, Fukudo S, Matsuoka H, Hongo M. Abnormal electroencephalogram in irritable bowel syndrome. Scand J Gastroenterol 1999;34:478-84.
37. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol 1990;259:G355-63.
38. Paran H, Silverberg D, Mayo A, Shwartz I, et al. Treatment of acute colonic pseudoobstruction with neostigmine. Am J Coll Surg 2000;190:315-8.
39. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, et al. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann Intern Med 1994;121:590-1.
40. Pennathur A, Cioppi M, Fayad JB, Little AG. Erythromycin, motilin, and the esophagus. Surgery 1993;114:295-8.
41. Ponec RJ, Saunders MD, Kimmey MB. Neostigmin for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999;341:137-41.
42. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499-510.
43. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
44. Rajagopalan M, Kurian G, John J. Symptom relieve with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-41.
45. Randall CW. Amitriptyline improves the quality of life in patients with non-ulcer dyspepsia. Gastroenterology 1998;114:A265.
46. Reboa G, Arnulfo G, Frascio M, Di Somma C, et al. Colon motility and colo-anal reflexes in chronic idiopathic constipation. Effects of a novel enterokinetic agent cisapride. Eur J Clin Pharmacol 1984:26:745-8.
47. Richards RD, Valenzuela GA, Davenport KG, Fisher KL, et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993;38:811-6.
48. Richter JE, Dalton CB, Bradley LA, Castell DO. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology 1987;93:21-8.
49. Scott LJ, Perry CM. Tegaserod. Drugs 1999;58:491-6.
50. Storr M, Allescher HD. Esophageal pharmacology and treatment of primary motility disorders. Dis Esophagus 1999;12:241-57.
51. Storr M, Allescher HD. Current concepts on pathophysiology, diagnosis and treatment of diffuse esophageal spasm. Drugs 2001;61:579-91.
52. Storr M, Allescher HD, Rösch T, Born P, et al. Treatment of symptomatic diffuse esophageal spasm by injection of Botulinum toxin: a prospective study and long term follow up. Gastrointest Endosc 2001;54:754-9.
53. Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000;18:93-102.
54. Talley NJ. Visceral analgesics and functional dyspepsia: have we found the holy grail? Gut 1997;41:717-8.
55. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind, placebo-controlled study with mianserin. Scand J Gastroenterol 1996;31:318-25.
56. Traube M, Dubovik S, Lange RC, McCallum RW. The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1989;84:1259-62.
57. Triadafilopoulos G, Aaronson M, Sackel S, Burakoff R. Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 1991;36:260-7.
58. van Zanten SV, Jones M, Talley NJ. Cisapride for the treatment of non-ulcer dyspepsia: a meta-analysis of randomized controlled trials. Gastroenterology 1998;114:A323.
59. Viramontes B, McKinzie S, Pardi DS, Burton D, et al. Alosetron retards small bowel and overall colonic transit in diarrhoea-predominant irritable bowel syndrome. Gastroenterology 2000;118:A848.